MacroGenics & Servier Ink Pact for Novel Anti-Cancer Drug

MacroGenics and Servier have entered into an option for a license agreement for the development and commercialization of MGA271.

US-based biotechnology company MacroGenics, Inc. and French privately-held pharmaceutical company Servier announced yesterday that they have entered into an option for a license agreement for the development and commercialization of MGA271, MacroGenics’ proprietary product candidate.

MGA271 is a first-in-class, Fc-optimized monoclonal antibody that targets B7-H3 and is currently being studied in a Phase 1 clinical trial for the treatment of solid tumors.

Under the terms of the agreement, MacroGenics retains full development and commercialization rights to MGA271 in the U.S., Canada, Mexico, Japan, Korea and India, while Servier has an option to obtain an exclusive license covering the rest of the world.